Laura N. Deden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura N. Deden has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Eric J. Hazebroek
Vitalys Obesity Clinic, Part of Rijnstate Hospital, Arnhem, Netherlands
7 shared publications - Frits J. Berends
Department of Surgery, Rijnstate, Arnhem, The Netherlands
3 shared publications - Agnes A. M. Berendsen
Wageningen University & Research, Wageningen, Netherlands
2 shared publications - Cornelis H. Slump
Robotics And Mechatronics group, University of Twente, Enschede, The Netherlands
2 shared publications Edo O. Aarts
Vitalys Clinic, Velp, the Netherlands; Department of Surgery, Rijnstate Hospital, Arnhem, the Netherlands
2 shared publications- Elske van Den Berg
Novarum Center for Eating Disorders and Obesity, Amstelveen, Netherlands
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (10) , 5307-5315
The Association between Anxiety and/or Depression Symptoms with Gastrointestinal Complaints Five Years after Metabolic and Bariatric Surgery - a Cross-sectional Study
Introduction: Gastrointestinal (GI) symptoms are common following metabolic and bariatric surgery (MBS) and can significantly impair quality of life. Previous research indicates that anxiety and depressive symptoms could be associated with GI complaints. This study aims to investigate the association between anxiety and/or depressive symptoms and GI complaints five years after MBS. Methods: In this cross-sectional study 220 participants who underwent MBS were included. Self-reported anxiety and/or depressive symptoms were measured with the Hospital Anxiety and Depression Scale and GI complaints with the Gastrointestinal Symptom Rating Scale . Differences in GI complaint scores between participants with no, mild or severe anxiety and/or depression symptoms were assessed using Kruskal-Wallis and post-hoc tests. Furthermore, the association between anxiety and/or depressive symptom categories and moderately-severe to severe GI complaints (any GRSR item score ≥ 5 out of 7) was assessed by modified Cox regression. Results: Participants were on average 50 ± 11 years of age five years post-MBS, mostly female (81%) and predominantly underwent RYGB (87%). 28% reported anxiety and/or depressive symptoms, of which 15% mild and 13% severe. 42% of participants reported moderately-severe to severe GI complaints, of which 20% was severe. Participants with severe anxiety and/or depressive symptoms had significantly higher total and domain GI complaint scores (abdominal pain, reflux syndrome, constipation syndrome) than participants without these symptoms ( p <.001). Similar trends were found in participants with mild anxiety and/or depressive symptoms (total p <.001, reflux syndrome p =.048, constipation syndrome p =.005), the association with abdominal pain was on the borderline of significance ( p =.05). Participants with mild or severe anxiety and/or depressive symptoms respectively had a 1.75 (95%CI 0.98–3.11; not statistically significant) and 2.55 (95%CI 1.45–4.47) times higher risk (BMI and sleep adjusted prevalence ratio’s) of experiencing moderately-severe to severe GI complaints compared to those without. Conclusion: Participants 5-years post-MBS with mild to severe self-reported anxiety and/or depressive symptoms are at a higher risk of reporting more severe GI complaints. These findings underscore the need to assess and refer anxiety and/or depressive symptoms when counselling patients after MBS with GI complaints.
- 21 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (10) , 5307-5315
Open AccessThe Association between Anxiety and/or Depression Symptoms with Gastrointestinal Complaints Five Years after Metabolic and Bariatric Surgery - a Cross-sectional Study
Introduction: Gastrointestinal (GI) symptoms are common following metabolic and bariatric surgery (MBS) and can significantly impair quality of life. Previous research indicates that anxiety and depressive symptoms could be associated with GI complaints. This study aims to investigate the association between anxiety and/or depressive symptoms and GI complaints five years after MBS. Methods: In this cross-sectional study 220 participants who underwent MBS were included. Self-reported anxiety and/or depressive symptoms were measured with the Hospital Anxiety and Depression Scale and GI complaints with the Gastrointestinal Symptom Rating Scale . Differences in GI complaint scores between participants with no, mild or severe anxiety and/or depression symptoms were assessed using Kruskal-Wallis and post-hoc tests. Furthermore, the association between anxiety and/or depressive symptom categories and moderately-severe to severe GI complaints (any GRSR item score ≥ 5 out of 7) was assessed by modified Cox regression. Results: Participants were on average 50 ± 11 years of age five years post-MBS, mostly female (81%) and predominantly underwent RYGB (87%). 28% reported anxiety and/or depressive symptoms, of which 15% mild and 13% severe. 42% of participants reported moderately-severe to severe GI complaints, of which 20% was severe. Participants with severe anxiety and/or depressive symptoms had significantly higher total and domain GI complaint scores (abdominal pain, reflux syndrome, constipation syndrome) than participants without these symptoms ( p <.001). Similar trends were found in participants with mild anxiety and/or depressive symptoms (total p <.001, reflux syndrome p =.048, constipation syndrome p =.005), the association with abdominal pain was on the borderline of significance ( p =.05). Participants with mild or severe anxiety and/or depressive symptoms respectively had a 1.75 (95%CI 0.98–3.11; not statistically significant) and 2.55 (95%CI 1.45–4.47) times higher risk (BMI and sleep adjusted prevalence ratio’s) of experiencing moderately-severe to severe GI complaints compared to those without. Conclusion: Participants 5-years post-MBS with mild to severe self-reported anxiety and/or depressive symptoms are at a higher risk of reporting more severe GI complaints. These findings underscore the need to assess and refer anxiety and/or depressive symptoms when counselling patients after MBS with GI complaints.
- Open Access
- 11 June 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (7) , 1-14
The value of Continuous Remote Monitoring in Clinical Decision Making After Same-day Discharge Metabolic Bariatric Surgery
Introduction: Remote assessment of patients after same-day discharge metabolic and bariatric surgery (MBS) might be improved by continuous remote monitoring (CRM), because it provides heart and respiratory rate (HR, RR), alongside patient complaints. This study aimed to evaluate the added value of CRM on clinical decision making in the remote assessment of patients after same-day discharge MBS. Methods: A nationwide survey among MBS healthcare professionals ( n = 23) evaluated the clinical applicability of remote monitoring with general questions and its influence on clinical decision making using fictitious patient cases. Additionally, in a retrospective cohort study ( n = 213), current remote patient assessment, HR and RR, technical sensor performance and patient satisfaction in (non-)readmitted patients who underwent same-day discharge MBS was evaluated. Results: The survey showed that HR and RR along with complaints does not lead to uniform treatment policies, and only 54% of healthcare professionals always use CRM vital signs in patient assessment. The cohort study shows that CRM data was used in only 20% of remote patient assessments, however when CRM data was used, all patients with normal data but with complaints were still referred to the emergency department. Additionally, no statistically significant differences were found in HR and RR between readmitted ( n = 14) and non-readmitted patients ( n = 199), 49% of HR and 43% of RR data were missing and 72% of patients would have undergone same-day discharge MBS without CRM. Conclusion: For this specific low-risk population, CRM did not appear to influence clinical decision making after same-day discharge MBS, under the current implementation conditions.
- 11 June 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (7) , 1-14
Open AccessThe value of Continuous Remote Monitoring in Clinical Decision Making After Same-day Discharge Metabolic Bariatric Surgery
Introduction: Remote assessment of patients after same-day discharge metabolic and bariatric surgery (MBS) might be improved by continuous remote monitoring (CRM), because it provides heart and respiratory rate (HR, RR), alongside patient complaints. This study aimed to evaluate the added value of CRM on clinical decision making in the remote assessment of patients after same-day discharge MBS. Methods: A nationwide survey among MBS healthcare professionals ( n = 23) evaluated the clinical applicability of remote monitoring with general questions and its influence on clinical decision making using fictitious patient cases. Additionally, in a retrospective cohort study ( n = 213), current remote patient assessment, HR and RR, technical sensor performance and patient satisfaction in (non-)readmitted patients who underwent same-day discharge MBS was evaluated. Results: The survey showed that HR and RR along with complaints does not lead to uniform treatment policies, and only 54% of healthcare professionals always use CRM vital signs in patient assessment. The cohort study shows that CRM data was used in only 20% of remote patient assessments, however when CRM data was used, all patients with normal data but with complaints were still referred to the emergency department. Additionally, no statistically significant differences were found in HR and RR between readmitted ( n = 14) and non-readmitted patients ( n = 199), 49% of HR and 43% of RR data were missing and 72% of patients would have undergone same-day discharge MBS without CRM. Conclusion: For this specific low-risk population, CRM did not appear to influence clinical decision making after same-day discharge MBS, under the current implementation conditions.
- Open Access
- 20 January 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (5) , 1295-1300
Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass
Aims/hypothesis In people with type 2 diabetes and obesity, Roux-en-Y gastric bypass (RYGB) can induce remission of diabetes. While RYGB has been reported to improve beta cell function in individuals with type 2 diabetes, it is unclear whether this is accompanied by changes in beta cell mass. In this explorative proof-of-concept study, we compared beta cell mass, measured by [68Ga]Ga-NODAGA-exendin-4 positron emission tomography/computed tomography (PET/CT) imaging, between individuals achieving remission of type 2 diabetes following RYGB and those not achieving remission. Methods Individuals with (n=8) and without (n=9) remission of type 2 diabetes up to 4 years after RYGB were injected with 100 ± 5.6 MBq of [68Ga]Ga-NODAGA-exendin-4 to quantify beta cell mass using PET/CT imaging. Beta cell function was determined by the AUC for C-peptide and the ratio between the AUC for C-peptide and AUC for glucose obtained from a combined arginine stimulation test (ARGT) and OGTT. Acquired variables are expressed as mean ± SD or median (IQR) based on normality. Results Individuals with remission of type 2 diabetes had a shorter diabetes duration than those without remission. After RYGB, beta cell function was higher in individuals with remission of type 2 diabetes than individuals without remission, based on both ARGTs (AUCC-peptide/fasting glucose 1.1 ± 0.41 vs 0.32 ± 0.16 nmol × min/mmol, p=0.001) and OGTTs (AUCC-peptide:AUCglucose 0.15 [0.11–0.24] vs 0.032 [0.023–0.054], p=0.005). In contrast, beta cell mass did not differ between individuals with or without remission of type 2 diabetes (3.6 [3.4–5.4] vs 3.8 [1.9–4.5] kBq/MBq, p=0.87) and did not correlate with beta cell function or body weight parameters. HOMA2-%B, also representing beta cell function, was better in the remission group and significantly improved in these individuals after RYGB, whereas it remained unchanged in non-remitters. Conclusions/interpretation Individuals with remission of type 2 diabetes after RYGB have better beta cell function than those not achieving remission, but the groups did not differ with respect to beta cell mass. Our preliminary data argue against a stimulating effect of RYGB on beta cell mass, although revival of non-functional (so-called dormant) beta cells is a possible explanation for remission. Trial registration ClinicalTrials.gov NCT02542059 Graphical Abstract
- 20 January 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (5) , 1295-1300
Open AccessBeta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass
Aims/hypothesis In people with type 2 diabetes and obesity, Roux-en-Y gastric bypass (RYGB) can induce remission of diabetes. While RYGB has been reported to improve beta cell function in individuals with type 2 diabetes, it is unclear whether this is accompanied by changes in beta cell mass. In this explorative proof-of-concept study, we compared beta cell mass, measured by [68Ga]Ga-NODAGA-exendin-4 positron emission tomography/computed tomography (PET/CT) imaging, between individuals achieving remission of type 2 diabetes following RYGB and those not achieving remission. Methods Individuals with (n=8) and without (n=9) remission of type 2 diabetes up to 4 years after RYGB were injected with 100 ± 5.6 MBq of [68Ga]Ga-NODAGA-exendin-4 to quantify beta cell mass using PET/CT imaging. Beta cell function was determined by the AUC for C-peptide and the ratio between the AUC for C-peptide and AUC for glucose obtained from a combined arginine stimulation test (ARGT) and OGTT. Acquired variables are expressed as mean ± SD or median (IQR) based on normality. Results Individuals with remission of type 2 diabetes had a shorter diabetes duration than those without remission. After RYGB, beta cell function was higher in individuals with remission of type 2 diabetes than individuals without remission, based on both ARGTs (AUCC-peptide/fasting glucose 1.1 ± 0.41 vs 0.32 ± 0.16 nmol × min/mmol, p=0.001) and OGTTs (AUCC-peptide:AUCglucose 0.15 [0.11–0.24] vs 0.032 [0.023–0.054], p=0.005). In contrast, beta cell mass did not differ between individuals with or without remission of type 2 diabetes (3.6 [3.4–5.4] vs 3.8 [1.9–4.5] kBq/MBq, p=0.87) and did not correlate with beta cell function or body weight parameters. HOMA2-%B, also representing beta cell function, was better in the remission group and significantly improved in these individuals after RYGB, whereas it remained unchanged in non-remitters. Conclusions/interpretation Individuals with remission of type 2 diabetes after RYGB have better beta cell function than those not achieving remission, but the groups did not differ with respect to beta cell mass. Our preliminary data argue against a stimulating effect of RYGB on beta cell mass, although revival of non-functional (so-called dormant) beta cells is a possible explanation for remission. Trial registration ClinicalTrials.gov NCT02542059 Graphical Abstract
- Open Access
- 28 August 2025
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 50 (2) , 331-338
Four-dimensional Computed Tomography Imaging in Primary Hyperparathyroidism: Multireader Multicase Study of Both Neuroradiologists and General Radiologists of Imaging Approaches With Less Phases
Objective: Primary hyperparathyroidism (PHPT) is commonly caused by parathyroid adenomas (PAs), and four-dimensional computed tomography (4DCT) is increasingly used for localising PAs due to its high sensitivity and specificity. However, the relative high radiation dose of 4DCT may limit its widespread use as first line imaging in some settings. A reduced phase protocol and enhancement maps, which highlight relative enhancement differences between the nonenhanced and arterial phases, have been proposed as ways to reduce radiation exposure without compromising diagnostic accuracy. This study aims to assess whether reduced 4DCT protocols can maintain diagnostic performance and if the enhancement map can further assist in adenoma localisation. Methods: This retrospective study included 27 PHPT patients, with both single and double adenomas, and some ectopic cases and 3 secondary HPT patients. Five-phase combinations derived from our institution’s 4-phase protocol were evaluated using a multireader, multicase approach involving experienced neuroradiologists and general radiologists. The phases tested included combinations of nonenhanced, arterial, venous, and delayed venous phases. An enhancement map was introduced as one of the phases. Readers were asked to identify adenomas and assign confidence levels. Performance metrics, including sensitivity, specificity, and area under the curve (AUC), were calculated, and noninferiority tests compared the results to the current 4-phase protocol. Results: Sensitivity of the total group was between 0.64 and 0.70 with a specificity between 0.94 and 0.97. AUC were between 0.80 and 0.84. All reduced phase combinations were noninferior to the 4-phase protocol. Neuroradiologists achieved noninferior results with 1-phase to 3-phase protocols, while general radiologists required at least 3-phases. The enhancement map did not improve sensitivity or specificity, although readers found it useful as a supplementary tool for identifying lesions. Artefacts, especially in ectopic locations, reduced its effectiveness. Conclusions: This study supports the use of reduced 4DCT protocols for PHPT. A 1-phase or 2-phase protocol is recommended for experienced radiologists, while a 3-phase protocol is suitable for less experienced radiologists.
- 28 August 2025
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 50 (2) , 331-338
Open AccessFour-dimensional Computed Tomography Imaging in Primary Hyperparathyroidism: Multireader Multicase Study of Both Neuroradiologists and General Radiologists of Imaging Approaches With Less Phases
Objective: Primary hyperparathyroidism (PHPT) is commonly caused by parathyroid adenomas (PAs), and four-dimensional computed tomography (4DCT) is increasingly used for localising PAs due to its high sensitivity and specificity. However, the relative high radiation dose of 4DCT may limit its widespread use as first line imaging in some settings. A reduced phase protocol and enhancement maps, which highlight relative enhancement differences between the nonenhanced and arterial phases, have been proposed as ways to reduce radiation exposure without compromising diagnostic accuracy. This study aims to assess whether reduced 4DCT protocols can maintain diagnostic performance and if the enhancement map can further assist in adenoma localisation. Methods: This retrospective study included 27 PHPT patients, with both single and double adenomas, and some ectopic cases and 3 secondary HPT patients. Five-phase combinations derived from our institution’s 4-phase protocol were evaluated using a multireader, multicase approach involving experienced neuroradiologists and general radiologists. The phases tested included combinations of nonenhanced, arterial, venous, and delayed venous phases. An enhancement map was introduced as one of the phases. Readers were asked to identify adenomas and assign confidence levels. Performance metrics, including sensitivity, specificity, and area under the curve (AUC), were calculated, and noninferiority tests compared the results to the current 4-phase protocol. Results: Sensitivity of the total group was between 0.64 and 0.70 with a specificity between 0.94 and 0.97. AUC were between 0.80 and 0.84. All reduced phase combinations were noninferior to the 4-phase protocol. Neuroradiologists achieved noninferior results with 1-phase to 3-phase protocols, while general radiologists required at least 3-phases. The enhancement map did not improve sensitivity or specificity, although readers found it useful as a supplementary tool for identifying lesions. Artefacts, especially in ectopic locations, reduced its effectiveness. Conclusions: This study supports the use of reduced 4DCT protocols for PHPT. A 1-phase or 2-phase protocol is recommended for experienced radiologists, while a 3-phase protocol is suitable for less experienced radiologists.
- Open Access
- 5 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (4) , 1423-1430
Preoperative Mental Disorders and Hospital Healthcare Use in the First Year After Metabolic Bariatric Surgery: A Retrospective Study
Background: Mental disorders are relatively common in individuals who undergo metabolic bariatric surgery (MBS). Prior research suggests that mental disorders may relate to increased healthcare use after MBS. We retrospectively explored the association between preoperative mental health disorders and healthcare use in the first postoperative year. Methods: Patients who underwent primary MBS and had a structured preoperative psychological assessment report were included. Data on healthcare use was collected as the total number of non-routine healthcare appointments including inpatient, outpatient, and emergency department visits. Additionally, gastrointestinal (GI) healthcare use at the radiology, gastroenterology, and emergency departments was analyzed separately. Results: Of the 944 included patients, 261 (28%) had a preoperatively diagnosed mental disorder. Most prevalent were depressive disorders, anxiety disorders, and eating disorders. Patients with a preoperative mental disorder had a 15% (adjusted, CI 1.04–1.27, p = 0.005) higher rate of total healthcare use compared to those without. Among patients who had any GI-related healthcare, those with a mental disorder had a 61% higher rate of GI-related healthcare use (CI 1.02–2.55, p = 0.041). Patients with a mental disorder tended to have 20% lower odds of having no GI-related healthcare appointments (unadjusted, not statistically significant, CI 0.37–1.74, p = 0.568). Conclusion: The presence of preoperative mental disorders was weakly related to higher total non-routine hospital healthcare use in the first year after MBS. Models explained only 5–13% of the variation in appointment frequency, meaning unmeasured and/or unknown factors play a role in healthcare use.
- 5 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (4) , 1423-1430
Open AccessPreoperative Mental Disorders and Hospital Healthcare Use in the First Year After Metabolic Bariatric Surgery: A Retrospective Study
Background: Mental disorders are relatively common in individuals who undergo metabolic bariatric surgery (MBS). Prior research suggests that mental disorders may relate to increased healthcare use after MBS. We retrospectively explored the association between preoperative mental health disorders and healthcare use in the first postoperative year. Methods: Patients who underwent primary MBS and had a structured preoperative psychological assessment report were included. Data on healthcare use was collected as the total number of non-routine healthcare appointments including inpatient, outpatient, and emergency department visits. Additionally, gastrointestinal (GI) healthcare use at the radiology, gastroenterology, and emergency departments was analyzed separately. Results: Of the 944 included patients, 261 (28%) had a preoperatively diagnosed mental disorder. Most prevalent were depressive disorders, anxiety disorders, and eating disorders. Patients with a preoperative mental disorder had a 15% (adjusted, CI 1.04–1.27, p = 0.005) higher rate of total healthcare use compared to those without. Among patients who had any GI-related healthcare, those with a mental disorder had a 61% higher rate of GI-related healthcare use (CI 1.02–2.55, p = 0.041). Patients with a mental disorder tended to have 20% lower odds of having no GI-related healthcare appointments (unadjusted, not statistically significant, CI 0.37–1.74, p = 0.568). Conclusion: The presence of preoperative mental disorders was weakly related to higher total non-routine hospital healthcare use in the first year after MBS. Models explained only 5–13% of the variation in appointment frequency, meaning unmeasured and/or unknown factors play a role in healthcare use.
- Open Access
- 3 November 2023
- Published by Springer Nature in Obesity Surgery
- Vol. 33 (12) , 3746-3754
Preoperative Weight Gain Is Not Related to Lower Postoperative Weight Loss, But to Lower Total Weight Loss up to 3 Years After Bariatric-Metabolic Surgery
Introduction: Weight loss prior to bariatric-metabolic surgery (BMS) is recommended in most bariatric centers. However, there is limited high-quality evidence to support mandatory preoperative weight loss. In this study, we will evaluate whether weight gain prior to primary BMS is related to lower postoperative weight loss. Methods: A retrospective analysis of prospectively collected data was performed. Preoperative weight loss (weight loss from start of program to day of surgery), postoperative weight loss (weight loss from day of surgery to follow-up), and total weight loss (weight loss from start of program to follow-up) were calculated. Five groups were defined based on patients’ preoperative weight change: preoperative weight loss of >5 kg (group I), 3–5 kg (group II), 1–3 kg (group III), preoperative stable weight (group IV), and preoperative weight gain >1 kg (group V). Linear mixed models were used to compare the postoperative weight loss between group V and the other four groups (I–IV). Results: A total of 1928 patients were included. Mean age was 44 years, 78.6% were female, and preoperative BMI was 43.7 kg/m2. Analysis showed significantly higher postoperative weight loss in group V, compared to all other groups at 12, 24, and 36 months follow-up. Up to three years follow-up, highest total weight loss was observed in group I. Conclusion: Weight gain before surgery should not be a reason to withhold a bariatric-metabolic operation. However, patients with higher preoperative weight loss have higher total weight loss. Therefore, preoperative weight loss should be encouraged prior to bariatric surgery. Graphical
- 3 November 2023
- Published by Springer Nature in Obesity Surgery
- Vol. 33 (12) , 3746-3754
Open AccessPreoperative Weight Gain Is Not Related to Lower Postoperative Weight Loss, But to Lower Total Weight Loss up to 3 Years After Bariatric-Metabolic Surgery
Introduction: Weight loss prior to bariatric-metabolic surgery (BMS) is recommended in most bariatric centers. However, there is limited high-quality evidence to support mandatory preoperative weight loss. In this study, we will evaluate whether weight gain prior to primary BMS is related to lower postoperative weight loss. Methods: A retrospective analysis of prospectively collected data was performed. Preoperative weight loss (weight loss from start of program to day of surgery), postoperative weight loss (weight loss from day of surgery to follow-up), and total weight loss (weight loss from start of program to follow-up) were calculated. Five groups were defined based on patients’ preoperative weight change: preoperative weight loss of >5 kg (group I), 3–5 kg (group II), 1–3 kg (group III), preoperative stable weight (group IV), and preoperative weight gain >1 kg (group V). Linear mixed models were used to compare the postoperative weight loss between group V and the other four groups (I–IV). Results: A total of 1928 patients were included. Mean age was 44 years, 78.6% were female, and preoperative BMI was 43.7 kg/m2. Analysis showed significantly higher postoperative weight loss in group V, compared to all other groups at 12, 24, and 36 months follow-up. Up to three years follow-up, highest total weight loss was observed in group I. Conclusion: Weight gain before surgery should not be a reason to withhold a bariatric-metabolic operation. However, patients with higher preoperative weight loss have higher total weight loss. Therefore, preoperative weight loss should be encouraged prior to bariatric surgery. Graphical
- Open Access
- 4 July 2022
- Published by Cambridge University Press (CUP) in Public Health Nutrition
- Vol. 25 (10) , 2731-2741
Relative validity of a short screener to assess diet quality in patients with severe obesity before and after bariatric surgery
Objective: To determine the relative validity and reproducibility of the Eetscore FFQ, a short screener for assessing diet quality, in patients with (severe) obesity before and after bariatric surgery (BS).Design: The Eetscore FFQ was evaluated against 3-d food records (3d-FR) before (T0) and 6 months after BS (T6) by comparing index scores of the Dutch Healthy Diet index 2015 (DHD2015-index). Relative validity was assessed using paired t tests, Kendall’s tau-b correlation coefficients (τb), cross-classification by tertiles, weighted kappa values (kw) and Bland–Altman plots. Reproducibility of the Eetscore FFQ was assessed using intraclass correlation coefficients (ICC).Setting: Regional hospital, the Netherlands.Participants: Hundred and forty participants with obesity who were scheduled for BS.Results: At T0, mean total DHD2015-index score derived from the Eetscore FFQ was 10·2 points higher than the food record-derived score (P < 0·001) and showed an acceptable correlation (τb = 0·42, 95 % CI: 0·27, 0·55). There was a fair agreement with a correct classification of 50 % (kw = 0·37, 95 % CI: 0·25, 0·49). Correlation coefficients of the individual DHD components varied from 0·01–0·54. Similar results were observed at T6 (τb = 0·31, 95 % CI: 0·12, 0·48, correct classification of 43·7 %; kw = 0·25, 95 % CI: 0·11, 0·40). Reproducibility of the Eetscore FFQ was good (ICC = 0·78, 95 % CI: 0·69, 0·84).Conclusion: The Eetscore FFQ showed to be acceptably correlated with the DHD2015-index derived from 3d-FR, but absolute agreement was poor. Considering the need for dietary assessment methods that reduce the burden for patients, practitioners and researchers, the Eetscore FFQ can be used for ranking according to diet quality and for monitoring changes over time.
- 4 July 2022
- Published by Cambridge University Press (CUP) in Public Health Nutrition
- Vol. 25 (10) , 2731-2741
Open AccessRelative validity of a short screener to assess diet quality in patients with severe obesity before and after bariatric surgery
Objective: To determine the relative validity and reproducibility of the Eetscore FFQ, a short screener for assessing diet quality, in patients with (severe) obesity before and after bariatric surgery (BS).Design: The Eetscore FFQ was evaluated against 3-d food records (3d-FR) before (T0) and 6 months after BS (T6) by comparing index scores of the Dutch Healthy Diet index 2015 (DHD2015-index). Relative validity was assessed using paired t tests, Kendall’s tau-b correlation coefficients (τb), cross-classification by tertiles, weighted kappa values (kw) and Bland–Altman plots. Reproducibility of the Eetscore FFQ was assessed using intraclass correlation coefficients (ICC).Setting: Regional hospital, the Netherlands.Participants: Hundred and forty participants with obesity who were scheduled for BS.Results: At T0, mean total DHD2015-index score derived from the Eetscore FFQ was 10·2 points higher than the food record-derived score (P < 0·001) and showed an acceptable correlation (τb = 0·42, 95 % CI: 0·27, 0·55). There was a fair agreement with a correct classification of 50 % (kw = 0·37, 95 % CI: 0·25, 0·49). Correlation coefficients of the individual DHD components varied from 0·01–0·54. Similar results were observed at T6 (τb = 0·31, 95 % CI: 0·12, 0·48, correct classification of 43·7 %; kw = 0·25, 95 % CI: 0·11, 0·40). Reproducibility of the Eetscore FFQ was good (ICC = 0·78, 95 % CI: 0·69, 0·84).Conclusion: The Eetscore FFQ showed to be acceptably correlated with the DHD2015-index derived from 3d-FR, but absolute agreement was poor. Considering the need for dietary assessment methods that reduce the burden for patients, practitioners and researchers, the Eetscore FFQ can be used for ranking according to diet quality and for monitoring changes over time.
- Open Access
- 15 December 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (12) , 1647
Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET
Stimulation of glucagon-like peptide-1 (GLP-1) receptors increases the insulin release in the pancreas during high glucose levels, and also stimulates a feeling of satiety. Likewise, synthetic GLP-1 receptor agonists derived from exendin are used successfully in the treatment of type-2 diabetes mellitus and obesity. Interestingly, preclinical and clinical studies further suggest that GLP-1 receptor agonists may decrease motor, behavioral, and cognitive symptoms in (animal models) Parkinson’s disease and Alzheimer’s disease and may slow down neurodegeneration. These observations suggest stimulation of GLP-1 receptors in the brain. The GLP-1 positron emission tomography (PET) tracer 68Ga-NODAGA-exendin-4 has been developed and successfully used for imaging in humans. In an ongoing study on the effects of bariatric surgery on GLP-1 receptor expression, we performed 68Ga-NODAGA-exendin-4 PET in obese subjects. Here we evaluated whether GLP-1 receptor binding could be visualized in the central nervous system in 10 obese subjects (seven woman; body mass index: mean ± SD: 39 ± 4.4 kg/m2) before bariatric surgery. Although we observed clear uptake in the pituitary area (mean SUVmax 4.3 ± 2.3), we found no significant uptake in other parts of the brain. We conclude that 68Ga-NODAGA-exendin-4 PET cannot be used to analyze GLP-1 receptors in the brain of obese subjects.
- 15 December 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (12) , 1647
Open AccessBrain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET
Stimulation of glucagon-like peptide-1 (GLP-1) receptors increases the insulin release in the pancreas during high glucose levels, and also stimulates a feeling of satiety. Likewise, synthetic GLP-1 receptor agonists derived from exendin are used successfully in the treatment of type-2 diabetes mellitus and obesity. Interestingly, preclinical and clinical studies further suggest that GLP-1 receptor agonists may decrease motor, behavioral, and cognitive symptoms in (animal models) Parkinson’s disease and Alzheimer’s disease and may slow down neurodegeneration. These observations suggest stimulation of GLP-1 receptors in the brain. The GLP-1 positron emission tomography (PET) tracer 68Ga-NODAGA-exendin-4 has been developed and successfully used for imaging in humans. In an ongoing study on the effects of bariatric surgery on GLP-1 receptor expression, we performed 68Ga-NODAGA-exendin-4 PET in obese subjects. Here we evaluated whether GLP-1 receptor binding could be visualized in the central nervous system in 10 obese subjects (seven woman; body mass index: mean ± SD: 39 ± 4.4 kg/m2) before bariatric surgery. Although we observed clear uptake in the pituitary area (mean SUVmax 4.3 ± 2.3), we found no significant uptake in other parts of the brain. We conclude that 68Ga-NODAGA-exendin-4 PET cannot be used to analyze GLP-1 receptors in the brain of obese subjects.
- 1 July 2019
- Published by Springer Nature in Obesity Surgery
- Vol. 29 (10) , 3095-3102
Treatment of Severe Protein Malnutrition After Bariatric Surgery
Severe protein malnutrition, with a serum albumin < 25 g/L, is one of the complications that may develop after bariatric surgery. It is associated with increased morbidity and mortality and requires timely diagnosis and appropriate treatment to prevent rapid clinical deterioration. However, evidence-based recommendations for a specific treatment approach are currently not available. The present study describes the efficacy of a newly developed treatment regimen for post-bariatric patients presenting with severe hypoalbuminemia.
- 1 July 2019
- Published by Springer Nature in Obesity Surgery
- Vol. 29 (10) , 3095-3102
Treatment of Severe Protein Malnutrition After Bariatric Surgery
Severe protein malnutrition, with a serum albumin < 25 g/L, is one of the complications that may develop after bariatric surgery. It is associated with increased morbidity and mortality and requires timely diagnosis and appropriate treatment to prevent rapid clinical deterioration. However, evidence-based recommendations for a specific treatment approach are currently not available. The present study describes the efficacy of a newly developed treatment regimen for post-bariatric patients presenting with severe hypoalbuminemia.
- Open Access
- 1 September 2018
- Published by Elsevier in Biological Psychology
- Vol. 137, 34-41
Altered neural inhibition responses to food cues after Roux-en-Y Gastric Bypass
- 1 September 2018
- Published by Elsevier in Biological Psychology
- Vol. 137, 34-41
Open AccessAltered neural inhibition responses to food cues after Roux-en-Y Gastric Bypass